Physician profile
Tabitha Townsend
NPI 1235423070
$4,773.96
in general payments reported to CMS, 2019-2025
42 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $224 · 2021: $498 · 2022: $567 · 2023: $1,052 · 2024: $1,219 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.99 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $822.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $355.88 | 2021-2025 | Imfinzi, Calquence |
| Genentech USA, INC. | $237.34 | 2019-2024 | Venclexta, Gazyva, Tecentriq |
| E.R. Squibb & Sons, L.L.C. | $233.23 | 2020-2024 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $227.14 | 2019-2025 | Fruzaqla, Iclusig |
| Genzyme Corporation | $209.78 | 2019-2025 | |
| Seagen INC. | $208.22 | 2023 | Padcev, Adcetris |
| Amgen INC. | $191.64 | 2019-2023 | Lumakras |
| Glaxosmithkline, LLC. | $183.07 | 2021-2024 | Zejula, Ojjaara |
| Pfizer INC. | $176.88 | 2020-2025 | |
| Incyte Corporation | $145.83 | 2021-2025 | Jakafi |
| Taiho Oncology, INC. | $131.87 | 2019-2025 | |
| Stemline Therapeutics INC. | $113.70 | 2023-2025 | Orserdu |
| Janssen Biotech, INC. | $104.03 | 2022-2025 | Darzalex, Rybrevant, Talvey |
| Celgene Corporation | $93.62 | 2023-2025 | Reblozyl |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $91.79 | 2021-2022 | |
| Exelixis INC. | $89.04 | 2023-2025 | Cabometyx |
| Daiichi Sankyo INC. | $86.47 | 2023-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $85.40 | 2019-2025 | Keytruda, Lynparza |
| Abbvie INC. | $84.77 | 2024-2025 | |
| Lilly USA, LLC | $80.95 | 2021-2024 | Retevmo, Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $80.49 | 2022-2023 | |
| Array Biopharma INC | $76.61 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Gilead Sciences, INC. | $70.72 | 2023-2025 | Trodelvy |
| Csl Behring | $67.32 | 2022 | |
| Beone Medicines USA, INC. | $60.36 | 2025 | Tevimbra, Brukinsa |
| Regeneron Healthcare Solutions, INC. | $58.21 | 2024-2025 | Libtayo |
| Mirati Therapeutics, INC. | $43.85 | 2023 | Krazati |
| Eisai INC. | $42.16 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $42.02 | 2021 | |
| Springworks Therapeutics, INC. | $37.10 | 2024 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $37.03 | 2021-2025 | Qinlock, Romvimza |
| Astellas Pharma US INC | $34.19 | 2020-2024 | Xtandi |
| Sun Pharmaceutical Industries INC. | $31.08 | 2022-2023 | Yonsa, Odomzo |
| Jazz Pharmaceuticals INC. | $22.78 | 2025 | |
| Foundation Medicine, INC. | $20.51 | 2023 | |
| Clovis Oncology, INC. | $18.67 | 2022 | |
| Novo Nordisk INC | $17.79 | 2019 | |
| Dova Pharmaceuticals | $16.82 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.44 | 2019 | |
| Shire North American Group INC | $14.13 | 2019 | |
| Emd Serono, INC. | $13.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.